We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Epigenomic Method Developed to Detect Pancreatic Cancer

By LabMedica International staff writers
Posted on 24 Oct 2018
Pancreatic cancers are typically diagnosed at late stage where disease prognosis is poor as exemplified by a 5-year survival rate of 8.2%. More...
Earlier diagnosis would be beneficial by enabling surgical resection or earlier application of therapeutic regimens.

A non-invasive liquid biopsy assay that tracks epigenetic modifications linked to gene regulation and pancreatic cancer pathogenesis in circulating cell-free DNA (cfDNA) in patient blood samples has been developed and a link has been uncovered between an epigenomic signal in cfDNA and pancreatic cancer in patients.

A team of scientists working with Bluestar Genomics (San Francisco, CA, USA) investigated the detection of pancreatic ductal adenocarcinoma (PDAC) in a non-invasive manner by interrogating changes in 5-hydroxymethylation cytosine status (5hmC) of circulating cell free DNA in the plasma. The team first collected and isolated plasma samples from a cohort of 51 pancreatic cancer patients and 41 non-cancer controls, then enriched for and sequenced regions of interest.

The team used use a method called "click chemistry" to modify hydroxymethyl groups on cytosine by attaching biotin tags. They then enriched the biotinylated DNA fragments by using streptavidin-coated magnetic beads, which enables an effective "pull-down" assay to separate DNA molecules that contain 5hmC from those that do not contain the biomarker. The team then sequences the fragments using a NextSeq 550 instrument, generating the data that can be used to derive an epigenetic signature.

After performing a set of regression models on the sequenced data, the investigators found that PDAC patients possessed thousands of genes with different epigenomic signatures, including areas of enrichment and absence of 5hmC, compared to non-diseased individuals. By filtering the genes with the most differentially hydroxymethylated states, the team found genes that were previously linked to pancreas development or pancreatic cancer.

The team validated the method on external cohorts from previous studies that contained pancreatic cancer and healthy samples, producing an area under the curve of 74% to 97%. The authors of the study believe that sub-partitioning PDAC and non-cancer individuals into different categories will improve detection and classification of the disease. The study was posted on September 26, 2018, on the preprint server BioRxiv.

Related Links:
Bluestar Genomics


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Autoimmune Disease Diagnostic
Chorus ds-DNA-G
New
Staining Management Software
DakoLink
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
Image: Pancreatic cancer diagnosis (Photo courtesy of World Journal of Gastroenterology)

AI-Driven Preliminary Testing for Pancreatic Cancer Enhances Prognosis

Pancreatic cancer poses a major global health threat due to its high mortality rate, with 467,409 deaths and 510,992 new cases reported worldwide in 2022. Often referred to as the "king" of all cancers,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.